Scarica l'app Stockscreener
35.75
2.14%
0.75
Dopo l'orario di chiusura:
36.46
0.71
+1.99%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRNX Giù?
Forum
Previsione
Crinetics Pharmaceuticals Inc Borsa (CRNX) Ultime notizie
Citizens reiterates Crinetics stock rating on strong launch data By Investing.com - Investing.com Canada
CRNX Reiterates by HC Wainwright & Co. -- Price Target Maintained at $81 - GuruFocus
H.C. Wainwright reiterates Crinetics stock rating on durability data By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Crinetics (CRNX) Reveals Promising Long-Term Results for Palsoni - GuruFocus
In CAH trial, daily pill cut steroid doses as hormone levels fell - Stock Titan
Crinetics shows Phase 2 success for atumelnant in reducing hormones and glucocorticoid use in CAH patients - Pluang
Crinetics (CRNX) Shares New Phase 2 Study Results on Atumelnant - GuruFocus
Crinetics presents phase 2 data for CAH treatment atumelnant By Investing.com - Investing.com South Africa
Crinetics Presents Full Results From Phase 2 Trial of - GlobeNewswire
Crinetics Pharmaceuticals Presents Long-Term Efficacy and Safety Data for PALSONIFY at ENDO 2026 - Quiver Quantitative
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control - GlobeNewswire Inc.
Sector Gamma AS Makes New $5.35 Million Investment in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Crinetics Pharmaceuticals, Inc. (CRNX) reports Q1 loss, beats revenue estimates - MSN
Positive Outlook for Crinetics (CRNX) After Camurus' Regulatory Setback - GuruFocus
Analysts estimate Crinetics Pharmaceuticals, Inc. (CRNX) to report a decline in earnings: What to look out for - MSN
CRNX Reiterated by Citizens -- Price Target Maintained at $95 - GuruFocus
Citizens reiterates Crinetics stock rating on Palsonify launch strength - Investing.com UK
Crinetics Pharmaceuticals' (CRNX) Market Outperform Rating Reaffirmed at Citizens Jmp - MarketBeat
Citizens reiterates Crinetics stock rating on Palsonify launch strength By Investing.com - Investing.com South Africa
Crinetics Pharmaceuticals (CRNX) is One of the Best AI Driven Biotech Stocks, Here is Why - Insider Monkey
Crinetics Pharmaceuticals, Inc. $CRNX Shares Bought by GW&K Investment Management LLC - MarketBeat
Crinetics' Everyday Advocacy initiative to support Cushing's care - Cushing's Disease News
WINTON GROUP Ltd Sells 39,816 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Understanding the Setup: (CRNX) and Scalable Risk - Stock Traders Daily
Geode Capital Management LLC Trims Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
A Look At Crinetics Pharmaceuticals (CRNX) Valuation As New Endocrine Data Heads To ENDO 2026 - Yahoo Finance
Acromegaly Market Shows Strong Future Potential with Increasing Industry Investments by 2036 – DelveInsight | Crinetics, Camurus, Chiesi, Debiopharm International SA, AstraZeneca, Marea Therapeutics - Barchart.com
Crinetics Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations - marketscreener.com
Crinetics launches patient education program for endocrine diseases - Investing.com UK
Crinetics launches patient education program for endocrine diseases By Investing.com - Investing.com Australia
Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities - The Manila Times
New Everyday Advocacy tools help endocrine patients navigate care - Stock Titan
Crinetics (NASDAQ: CRNX) CEO reports 1.94M share gifts and trust transfers - Stock Titan
Crinetics Pharmaceuticals Highlights Positive Clinical Data for PALSONIFY™ and Atumelnant at ENDO 2026 Conference - Quiver Quantitative
Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations - The Manila Times
What Do Analysts Say About Crinetics Pharmaceuticals (CRNX)? - Insider Monkey
5 Under-the-Radar Stocks with Massive Upside for 2026 - Insider Monkey
The Technical Signals Behind (CRNX) That Institutions Follow - Stock Traders Daily
Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026 - The Manila Times
Crinetics management to meet investors at Jefferies healthcare event - Stock Titan
CRNX Stock Price, Quote & Chart | CRINETICS PHARMACEUTICALS IN (NASDAQ:CRNX) - ChartMill
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? - AOL.com
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Q4 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q3 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q2 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Crinetics shares jump on robust PALSONIFY uptake and encouraging trial results - MSN
Precision Trading with Crinetics Pharmaceuticals Inc. (CRNX) Risk Zones - Stock Traders Daily
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):